Eledon Pharmaceuticals, Inc. (ELDN) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped ELDN stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Eledon Pharmaceuticals appears positioned for substantial upside. Leveraging positive clinical trials, strategic funding achievements, and orphan drug upstream development provide a strong narrative for the company's potential growth. The stock is speculative but intriguing due to upside tail-risk opportunities. The saved 1-year distribution is P10 $2.6, P50 $8, and P90 $12.
Last analyzed · Model: gpt-4o
Eledon Pharmaceuticals, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.6 | Pessimistic plausible scenario |
| P50 | $8 | Median scenario |
| P90 | $12 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Eledon Pharmaceuticals has recently demonstrated positive trial results (such as for ELDN-001) and secured significant funding. Furthermore, it holds a strong analyst consensus with high implied price targets. These indicate substantial upside potential within the next year.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this ELDN analysis generated?
April 28, 2026.
Is this a guaranteed ELDN prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full ELDN stock analysis · ELDN sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.